PP193—Simultaneous LC-MS/MS Quantification of P-Glycoprotein and Cytochrome P450 Probe Substrates and Their Metabolites In Dried Blood Spots  by Bosilkovska, M. et al.
Poster Presentation Abstracts
2013 e77
PP192—Pharmacokinetics of selexiPag in 
subjects with severe renal imPairment 
comPared with healthy subjects
N. Fischer1*; H. Cruz1; S. Bruderer1; M. Petersen-Sylla2;  
A. Halabi2; and J. Dingemanse1
1Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, 
Switzerland; and 2CRS, Kiel, Germany
Introduction: Selexipag is a new prostacyclin receptor agonist, 
which is being investigated in Phase III studies for the treatment of 
pulmonary arterial hypertension (PAH). Renal function impairment 
can alter the disposition of a large number of drugs and since PAH 
patients may have impaired renal function, the aim of this study was 
to assess how severe renal function impairment (SRFI) may affect the 
pharmacokinetics (PK), safety, and tolerability of selexipag and its 
active metabolite (ACT-333679).
Patients (or Materials) and Methods: Sixteen subjects were enrolled 
in this 2-group Phase I study. Groups A and B were composed of 8 
subjects with SRFI and 8 healthy subjects, respectively. Subjects in 
Group B were matching with those in Group A, based on age, sex, 
race, and body mass index. Subjects received a single oral dose of 
400 µg selexipag and were monitored for 144 h (Group A) or 72 h 
(Group B). PK samples were analyzed by liquid chromatography 
coupled to tandem mass spectrometry. PK parameters of selexipag 
and ACT-333679 were explored using ratios of geometric means 
and their 90% CIs.
Results: PK results (geometric mean (95% CI)) are presented in the 
table below:
No relevant differences in plasma protein binding of selexipag 
and ACT-333679 were observed between both groups. Five sub-
jects reported 17 adverse events (AEs): 8 in Group A, 9 in Group B. 
Headache was the most frequently reported AE in both groups (4 
in each group). No clinically relevant changes in mean vital signs, 
electrocardiograms, clinical laboratory variables, including estimated 
glomerular filtration rate and urinalysis, were observed. No deaths 
or serious adverse events were reported.
Conclusion: Selexipag 400 µg was generally well tolerated in all sub-
jects. Compared with healthy subjects, a 1.7-fold increase in Cmax 
and AUC to selexipag was observed in subjects with SRFI. Similar 
results were obtained for ACT-333679, i.e., a 1.4-fold increase in 
Cmax and an approximately 1.7-fold increase in AUC in subjects 
with SRFI compared with healthy subjects.
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Introduction: Modifications in cytochrome P450 (CYP) and/or 
transporter activities (such as P-glycoprotein [P-gp]) can result in 
important pharmacokinetic variability and are the underlying mecha-
nism of many drug–drug interactions. CYP and P-gp activity can be 
assessed by the in vivo administration of a cocktail of probe drugs 
each of which is metabolized by 1 specific cytochrome or transported 
by P-gp.
Patients (or Materials) and Methods: In this study, a single 
HPLC-MS/MS method has been developed for the simultaneous 
quantification of P-gp (fexofenadine) and CYP probe substrates (caf-
feine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, 
omeprazole for CYP2C19, dextromethorphan for CYP2D6 and 
midazolam for CYP3A), and their metabolites in dried blood spots 
(DBS). Substances were extracted from DBS (10 µL) using methanol. 
DBS analysis was performed using a LC-MS/MS system consisting 
of a 5500QTrap® triple quadrupole linear ion trap (QqQLIT) mass 
spectrometer equipped with a TurboIon SprayTM interface and an 
Ultimate 3000 RS instrument as LC system.
Results: The method was validated according to international crite-
ria. The intermediate precision was < 10% and the accuracy was in 
the interval (92.2%–111.1%) for all substances and all concentra-
tions tested. A linear response was observed for the following con-
centration ranges: 1 to 200 ng/mL for bupropion, hydroxybupropion, 
and fexofenadine; 0.1 to 100 ng/mL for midazolam; 0.2 to 200 ng/
mL for omeprazole, hydroxyomeprazole, hydroxymidazolam, and 
dextromethorphan; 0.5 to 500 ng/mL for dextrorphan; 50 to 10,000 
ng/mL for caffeine and paraxanthine; 50 to 2500 ng/mL for flurbi-
profen and 5 to 1000 ng/mL for hydroxyflurbiprofen. All substances 
were stable in DBS stored at room temperature for at least 15 days. 
The method has been successfully applied to a pharmacokinetic study 
where healthy male volunteers have received a low-dose cocktail of 
the here described P-gp and CYP probe substances. Metabolic ratios 
were determined for all CYP probe drugs and a good correlation was 
observed when drug concentrations in capillary DBS samples were 
compared with venous plasma samples.
Conclusion: DBS is a suitable sampling method for cytochromes and 
P-glycoprotein phenotyping.
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Introduction: Selexipag is a new prostacyclin receptor agonist, which 
is being investigated in Phase III studies for the treatment of pulmo-
nary arterial hypertension (PAH). Selexipag is eliminated for > 90% 
by the liver and because PAH patients may suffer from liver impair-
ment, the aim of this study was to assess how different degrees of 
liver impairment may affect the pharmacokinetics (PK), safety, and 
tolerability of selexipag and its active metabolite (ACT-333679).
Patients (or Materials) and Methods: Twenty-six subjects were 
enrolled in this 4-group Phase 1 study. Group A, B, C, and D were 
composed of 8 subjects with mild liver impairment, 8 subjects with 
moderate liver impairment, 2 subjects with severe liver impairment, 
and 8 healthy subjects, respectively. Subjects of Group D were match-
ing with those of Group B, based on age, sex, body weight, and 
height. Subjects received a single oral dose of selexipag (400 µg for 
Parameter Group A Group B
Selexipag ACT-333679 Selexipag ACT-333679
Cmax1 [ng/mL] 5.4 (3.9–7.4) 7.3 (6.1–8.7) 3.1 (2.1–4.5) 5.1 (3.2–8.2)
Tmax2 [h] 2.0 (1.0–5.0) 4.0 (1.5–6.0) 1.5 (0.5–6.0) 4.5 (2.0–8.0)
t1/23 [h] 1.0 (0.7–1.5) 13.4 (7.1–25.4) 1.4 (0.8–2.2) 8.3 (7.0–9.9)
AUC0–∞4 
[ng*h/mL]
17.1 (13.4–
21.6)
70.6 (29.3–
170.3)
9.9 (7.4–13.2) 43.7 (14.6–
131.1)
1peak concentration; 2time to reach Cmax; median (range); 3terminal half-life; 4exposure 
from 0 to ∞.
